Products for Research Use Only
RegisterLogin

Imlunestrant

CAT: 0804-HY-145572-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-145572-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Imlunestrant (LY-3484356) is an orally active, potent and selective estrogen receptor degrader (SERD) with pure antagonistic properties. Imlunestrant results in sustained inhibition of ER-dependent gene transcription and cell growth. Imlunestrant can be used for the research of ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC) [1][2].
CAS Number
2408840-26-4
Product Name Alternative
LY-3484356
UNSPSC
12352005
Target
Estrogen Receptor/ERR
Type
Reference compound
Related Pathways
Vitamin D Related/Nuclear Receptor
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/imlunestrant.html
Concentration
10mM
Purity
99.72
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
OC1=CC2=NC=C(C3=CC=C(C(F)(F)F)C=C3O[C@]4([H])C5=CC=C(C=C5)OCCN6CC(C6)CF)C4=C2C=C1
Molecular Formula
C29H24F4N2O3
Molecular Weight
524.51
References & Citations
[1]Komal L. Jhaveri, et al. A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC) : Results from the EMBER study. 2021 ASCO Annual Meeting I.|[2]Cristina Hernando, et al. Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective. Int. J. Mol. Sci. 2021, 22 (15), 7812.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched

Alternative Products

CatalogName
BA9222-1Imlunestrant
MBS5816375Imlunestrant tosylate

Popular Products